×
About 2,478 results

ALLMedicine™ Anal Cancer Center

Research & Reviews  812 results

Exploring the Anal Microbiome in HIV positive and high risk HIV negative Women.
https://doi.org/10.1089/AID.2020.0245
AIDS Research and Human Retroviruses; Wells J, Bai J et. al.

Jan 20th, 2022 - This exploratory study sought to characterize the anal microbiome and explore associations among the anal microbiome, risk factors for anal cancer, and clinical factors. A pilot sample of 50 HIV infected and high-risk HIV negative women were recru...

Trends in incidence and survival from anal cancer and incidence of high-grade anal intr...
https://doi.org/10.1016/j.canep.2022.102099
Cancer Epidemiology; Urbute A, Munk C et. al.

Jan 17th, 2022 - The aim of the current study was to assess temporal trends in incidence of anal squamous cell carcinomas (SCC) and high-grade anal intraepithelial lesions (AIN2/3), and estimate survival from anal cancer and factors related to 5-year mortality in ...

Design of the anal cancer/HSIL outcomes research study (ANCHOR study): A randomized stu...
https://doi.org/10.1016/j.cct.2022.106679
Contemporary Clinical Trials; Lee JY, Lensing SY et. al.

Jan 13th, 2022 - It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high ...

Perceptions of Anal Cancer Risk Among HIV-Positive and High-Risk HIV-Negative Women.
https://doi.org/10.1097/LGT.0000000000000652
Journal of Lower Genital Tract Disease; Wells J, Chandler R et. al.

Jan 13th, 2022 - Women living with HIV (WLWH) have a greater risk of anal cancer than women without HIV; however, there are limited studies that examine awareness of anal cancer risk among WLWH and "high-risk" HIV-negative women. This study examines risk factors f...

Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A mult...
https://doi.org/10.1016/j.radonc.2021.12.050
Radiotherapy and Oncology : Journal of the European Socie... Martin D, Schreckenbach T et. al.

Jan 10th, 2022 - Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escala...

see more →

Guidelines  7 results

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
https://doi.org/10.1016/j.annonc.2021.06.015
Annals of Oncology : Official Journal of the European Soc... Rao S, Guren MG et. al.

Jun 28th, 2021 - Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Rao S,Guren MG,Khan K,Brown G,Renehan AG,|diagnosis,epidemiology,therapy,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0060
Journal of the National Comprehensive Cancer Network : JN... Benson AB, Venook AP et. al.

Jul 15th, 2018 - The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain les...

2016 IANS International Guidelines for Practice Standards in the Detection of Anal Canc...
https://doi.org/10.1097/LGT.0000000000000256
Journal of Lower Genital Tract Disease; Hillman RJ, Cuming T et. al.

Aug 26th, 2016 - To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2...

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and ...
https://doi.org/10.1093/annonc/mdu159
Annals of Oncology : Official Journal of the European Soc... Glynne-Jones R, Nilsson PJ et. al.

Jul 9th, 2014 - Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2014|Glynne-Jones R,Nilsson PJ,Aschele C,Goh V,Peiffert D,|diagnosis,therapy,standards,

see more →

Drugs  2 results see all →

Clinicaltrials.gov  31 results

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
https://clinicaltrials.gov/ct2/show/NCT03233711

Jan 6th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma. SECONDARY OBJECTIVES: I. To compar...

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
https://clinicaltrials.gov/ct2/show/NCT00798265

Oct 29th, 2021 - Background: Human papilloma virus (HPV) is one of the most common sexually transmitted diseases and a significant cause of cutaneous genital warts and anogenital cancer. Infection with high-risk, oncogenic HPV types, most commonly types 16 and 18,...

Study of Pomalidomide in Anal Cancer Precursors
https://clinicaltrials.gov/ct2/show/NCT03113942

Oct 12th, 2021 - This is a single centre open label phase II trial to determine the antitumor efficacy of the oral immunomodulatory agent pomalidomide in persistent human papillomavirus (HPV) -associated high grade squamous intra-epithelial lesions (HSIL) in patie...

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
https://clinicaltrials.gov/ct2/show/NCT02865135

Sep 9th, 2021 - This is a phase Ib/II clinical trial. DPX-E7 is a therapeutic vaccine, intended to treat HPV-related head and neck, cervical or anal cancer. DPX-E7 is an investigational vaccine and the FDA (the U.S. Food and Drug Administration) has not approved ...

CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas
https://clinicaltrials.gov/ct2/show/NCT02981862

Aug 31st, 2021 - The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer, Oral Cavity...

see more →

News  133 results

OncLive® Honors 14 Cancer Care Pioneers
https://www.onclive.com/view/onclive-honors-14-cancer-care-pioneers

Oct 15th, 2021 - OncLive® is honored to announce the 2021 Giants of the Cancer Care® inductees. The 14 winners are innovators of change whose invaluable contributions to the field have changed the trajectory of care across tumor types and improved the quality of l...

Staging System for HPV-Related Oropharynx Cancer Paves Way for Change
https://www.onclive.com/view/staging-system-for-hpvrelated-oropharynx-cancer-paves-way-for-change

Oct 6th, 2021 - Robert I. Haddad, MD Division of Head and Neck Oncology Dana-Farber Cancer Institute Professor of medicine Harvard Medical School Boston, Massachusetts A new staging system for head and neck cancers recognizes that patients with orophar...

Rectal Cancer Treatment Enters an Era of Personalized Medicine
https://www.onclive.com/view/rectal-cancer-treatment-enters-an-era-of-personalized-medicine

Oct 6th, 2021 - The constantly-evolving rectal cancer paradigm has entered an era of personalized treatment, according to Noam VanderWalde, MD, MS, who added that with the growing number of options available, a multidisciplinary team is needed to inform care deci...

ODAC Postpones Decision on Retifanlimab in Advanced Anal Cancer
https://www.onclive.com/view/odac-postpones-decision-on-retifanlimab-in-advanced-anal-cancer

Jul 26th, 2021 - In a 13 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) chose to hold off on a decision regarding accelerated approval for retifanlimab (INCMGA 0012) for the treatment of patients with locally advanced or metastatic squamous carcino...

Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA
https://www.medpagetoday.com/hematologyoncology/othercancers/93275

Jun 24th, 2021 - FDA advisors told the agency to wait on more data before approving an investigational immunotherapy for squamous carcinoma of the anal canal (SCAC), largely due to questions over the drug's activity. By a 13-4 margin, the Oncologic Drugs Advisory ...

see more →

Patient Education  6 results see all →